Promentis Pharmaceuticals
Business Services · Wisconsin, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
826 N Plankinton Ave Ste 400, Milwaukee,...Phone Number
(414) 238-2992Website
www.promentispharma.comRevenue
$10 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Promentis Pharmaceuticals
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing innovative therapies for neuropsychiatric disorders, with a particular emphasis on trichotillomania. The company aims to address the underlying pathology associated with this highly prevalent condition and other related disorders through novel oral compounds that engage a CNS target. Their leadership team consists of recognized experts in the biopharmaceutical industry and clinical fields pertaining to CNS disorders. Promentis is committed to redefining the possibilities in the treatment of neuropsychiatric conditions.Explore more
Promentis Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Promentis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Promentis Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Promentis Pharmaceuticals launches new products
Click to see if Promentis Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Promentis Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Promentis Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Promentis Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check if Promentis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Promentis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Promentis Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Promentis Pharmaceuticals
Compare insights from companies similar to Promentis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Promentis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Promentis Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Promentis Pharmaceuticals.
Promentis Pharmaceuticals financials insights
Gather financial insights about Promentis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Unspecified
$1.8M
2013
Unspecified
$750K
Private Equity
$820K
2014
Series B
$2.9M
2016
Private Equity
$8.8M
2017
Series C
$26M
Private Equity
$17.6M
2019
Unspecified
$2.5M
2021
Debt
$104K
Promentis Pharmaceuticals Tech Stack
A closer look at the technologies used by Promentis Pharmaceuticals
See more technologies
Most Recent Scoops
Funding
Promentis Pharmaceuticals has received an SBA PPP loan in the amount of $104,167 from Associated Bank resulting in the retention of 5 jobs.
Funding
, a biopharmaceutical company, has secured $2.5 million in debt funding.
Funding
Project
A high-level source has indicated the organization's largest upcoming finance and accounting related initiatives will focus on completing equity investments. Stacy Holland serves as Financial & Accounting Advisor.
Spending/Investment, Accounting, Financial Planning, Financial Systems
Project
Promentis Pharmaceuticals News & Media
Milwaukee Biotech company raises $2.5 million for trichotillomania research
Promentis Pharmaceuticals, Inc. has raised $2.5 million for the continued research of a cure for trichotillomania, a neuropsychiatric disorder.Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit
MILWAUKEE, Nov. 1, 2019 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced that Dr. Chad E. Beyer, Senior Vice President of R&D, will share clinical findings from Promentis'...Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
MILWAUKEE, Jan. 17, 2019 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced it has initiated dosing in a Phase 2 study for its lead compound, SXC-2023, for the...Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting
MILWAUKEE, Dec. 5, 2018 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced that Senior Vice President of R&D, Dr. Chad Beyer, will present nonclinical data and initial...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Promentis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on developing innovative therapies for neuropsychiatric disorders, with a particular emphasis on trichotillomania. The company aims to address the underlying pathology associated with this highly prevalent condition and other related disorders through novel oral c... Read More
